On September 17th, Boston Scientific announced that it has completed the acquisition of Silk Road Medical (Nasdaq: SILK) for a total price of approximately $1.18 billion (approximately RMB 8.4 billion). The acquisition price is a cash price of $27.50 per share, aimed at expanding its products and services in the vascular medical field.

It is worth noting that this is Boston Scientific's second "billion dollar acquisition" this year.

Premium of 38%, innovative technology wins the favor of giants
Silk Road Medical is an innovative medical device company located in California, USA, dedicated to reducing the risk of stroke and its destructive effects. The company has pioneered a new method for treating carotid artery disease called Transcranial Arterial Revascularization (TCAR), which is why it has gained favor from Boston Scientific and is willing to pay a premium of 38% to acquire the company for a whopping 8.4 billion yuan.

It is understood that TCAR is a clinically validated surgery that combines neuroprotective surgical principles with minimally invasive endovascular techniques for the treatment of carotid artery occlusion that poses a risk of stroke. TCAR is of great significance for the treatment of carotid artery occlusion. Prior to the development of TCAR by Silk Road Medical, patients with carotid artery disease had only two options: carotid endarterectomy (CEA) or femoral carotid stent implantation (TFCAS). Although these two treatment methods can treat some patients, they can bring many complications (such as cerebral infarction).

According to a study conducted overseas on nearly 400000 patients undergoing carotid artery reconstruction in the United States, the incidence of cerebral infarction and myocardial infarction after TCAR surgery is lower compared to endarterectomy; Compared with stent implantation, TCAR has lower rates of cerebral infarction and mortality after surgery. Large scale clinical studies have shown that TCAR is safer, which once again confirms the significant breakthrough of TCAR in the treatment of carotid artery occlusion.

Returning to the TCAR technology itself, Silk Road Medical's TCAR technology mainly includes two core products: ENROUTE Transcarotic Neuroprotection System and ENROUTE Transcarotic Stent System ® Transcranial stent system).

 ENROUTE Transcranial Thrombolysis Protection Device
The ENROUTE Transcranial Reflux Thrombosis Protection Device is used to reverse blood flow in the brain before passing through the lesion, providing embolic protection during angioplasty and stent placement procedures.

Unlike traditional methods that rely on filters placed remotely to capture blood clots, this device achieves embolization protection throughout the entire surgical period through blood reflux. Small and large fragments are collected through filters in the flow controller, and the filtered blood is returned through a sheath in the femoral vein, thereby achieving nerve protection similar to CEA. The ENROUTE carotid retrograde thrombus protection device is the core technology of TCAR surgery and the key difference from TFCAS surgery.

 ENROUTE ® Transcranial Stent System
The ENROUTE ® Transcranial Stent System is designed specifically for TCAR surgery, capable of automatically conforming to anatomical structures and providing long-term plaque stability to prevent future stroke.

The features of the system include: specific conveying length: 57mm conveying system, ergonomic and precise stent conveying; Optimized unit design: Provides maximum coverage for all open unit support designs, even capable of automatically adapting to the most difficult anatomical structures.

The 'buy buy buy' strategy leads to sustained growth in cardiovascular business
As mentioned earlier, this acquisition of Silk Road Medical is Boston Scientific's second "billion dollar acquisition" of the year. The previous one was on January 8th, when Boston Scientific acquired Axonics, a device manufacturer for treating urinary and intestinal dysfunction, for a total of $3.7 billion (approximately RMB 26.2 billion) in cash at a price of $71 per share.

In addition, this month, Boston Scientific also purchased two anastomotic leak solution products from Braun Medical - Eso SPONGE (a product used to treat upper gastrointestinal anastomotic leaks and perforation) and Endo SONGE (used to treat colorectal anastomotic leaks).

For many years, Boston has been adhering to its merger and acquisition strategy, tirelessly "buying and buying". With long-term development, Boston Scientific has become a leader in the medical device industry. Previously, in the Q2 2024 quarterly results released by Boston Scientific, the trend of revenue and business growth in the sector was also very promising.

In Q2 2024, Boston Scientific's revenue was $4.21 billion, with a net sales growth of 14.5%, of which the cardiovascular business accounted for 64% and the medical surgery business accounted for 36%.

By category, the electrophysiology segment in the cardiovascular business has experienced the fastest growth, with global net sales increasing by 121.9% and operational/organic growth by 124.6%. The growth of this sector is also attributed to its FARAPULSE, which was approved for listing in China on July 8th ™ The series of pulse electric field ablation products, which were first approved in the United States, experienced a surge in sales and continued to grow in sales on the European continent.

The acquisition of Silk Road Medical and the acquisition of TCAR technology this time adds another potential player to Boston Scientific's cardiovascular business, and the business sector has become increasingly diversified with multiple major acquisitions by Boston Scientific.

Source: https://news.yaozh.com/archive/44239.html

责编: editor